| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5912079 | Multiple Sclerosis and Related Disorders | 2016 | 36 Pages |
Abstract
This integrated analysis demonstrates that treatment of RRMS with daclizumab for periods of up to 6.5 years is associated with an acceptable safety profile with no evidence of cumulative toxicity over time.
Keywords
SMQDSMBMedDRASAERRMsIL-2ALTULNGGTASTAspartate aminotransferaseAlanine aminotransferaseSafetyinterleukin 2TolerabilityDaclizumabGastrointestinalMedical Dictionary for Regulatory ActivitiesSOCadverse eventIntramuscularSerious adverse eventDRESSclinical studyrelapsing-remitting multiple sclerosisMultiple sclerosisData Safety Monitoring BoardSystem organ classGamma-glutamyl transferase
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Gavin Giovannoni, Ludwig Kappos, Ralf Gold, Bhupendra O Khatri, Krzysztof Selmaj, Kimberly Umans, Steven J Greenberg, Marianne Sweetser, Jacob Elkins, Peter McCroskery,